Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tango Therapeutics, Inc.NASDAQ: TNGX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $29.19M rose 227.1% year over year, ahead of the +79.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 29.2% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.
Context
- Selling, general & admin amounted to 66.5% of revenue in FY2025, down 37.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $5.28M (-87.3%) for the fiscal year ending Dec 2026, a slowdown from the -5.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $29.19M+29.2% QoQ
- Last fiscal yearDec 2025
- $41.51M-5.1% YoY
- LTMSep 2026
- $76.77M+79.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 41.51M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- +23.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.51M | -5.1% |
| FY2024 | 2024-12-31 | 43.75M | +23.2% |
| FY2023 | 2023-12-31 | 35.5M | +18.2% |
| FY2022 | 2022-12-31 | 30.03M | +70.6% |
| FY2021 | 2021-12-31 | 17.6M | — |
Selling, General & Admin vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's LTM Sep 2026 selling, general & admin of $76.77M is the 4th highest of the 11 companies compared; the peer median is $47.62M.
- Its year-over-year change of +79.2% is the 2nd highest of 11, against a peer median of +6.3%.
- Over three fiscal years its annual growth of +11.4% compares with a peer median of +8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $328.54M | +157.1% | +66.4% | — | |
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Sep 2026 | $76.77M | +79.2% | +11.4% | — | |
| LTM Mar 2026 | $69.19M | +65.4% | +42.7% | 30.7% | |
| LTM Jun 2026 | $51.18M | -29.7% | -6.5% | 494.5% | |
| LTM Sep 2026 | $44.05M | +16.1% | +5.3% | — | |
| LTM Mar 2026 | $34.4M | -16.4% | -5.4% | 98.7% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M | -10.5% | +40.4% | — |
| LTM Mar 2026 | $21.38M | -22.5% | -9.9% | 127.9% | |
| Peer median (excluding TNGX) | $47.62M | +6.3% | +8.4% | 95.3% | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.28M |
| Gross Profit | 37.04M | 24.86M | 36.53M | 42.07M | 60.1M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.3% |
| Research & Development | 77.64M | 105.91M | 115.2M | 143.92M | 132.17M |
| Selling, General & Admin | 17.6M | 30.03M | 35.5M | 43.75M | 41.51M |
| Operating Expenses | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| EBITDA | (57.05M) | (106.51M) | (99.2M) | (127.6M) | (99.31M) |
| EBITDA Margin | -154.0% | -428.5% | -271.6% | -303.3% | -159.2% |
| Operating Income | (58.19M) | (111.07M) | (114.17M) | (145.6M) | (111.29M) |
| Operating Margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Interest Income | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 247K | 2.95M | 12.56M | 15.5M | 9.7M |
| Income Before Tax | (57.94M) | (108.12M) | (101.61M) | (130.09M) | (101.59M) |
| Pre-Tax Margin | -156.4% | -434.9% | -278.2% | -309.2% | -162.8% |
| Income Tax Expense | 292K | 54K | 134K | 208K | 4K |
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Net Margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| EPS (Basic) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| EPS (Diluted) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| Weighted Avg Shares | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
| Weighted Avg Shares (Diluted) | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.